Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Chemo Research S L currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units, indicating a broad spread of examination across the office. This lack of concentration suggests that the company's current patent applications cover a variety of specific sub-technologies within the broader pharmaceutical field, rather than being clustered under a single specialized review team.
PRAGANI, RAJAN is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. For a practitioner, this distribution means that prosecution strategies must be tailored to the individual tendencies of the different examiners, as there is no primary examiner handling a majority of the workload. The ratio of pending actions to examiners and art units reflects a diversified prosecution landscape for the company at this stage.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRAGANI, RAJAN | 1 | 52.4% | +71.4% |
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682824 | METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION | AZPURU, CARLOS A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18842742 | CHEWABLE ORAL CONTRACEPTIVE | PRAGANI, RAJAN | — |
| 18698961 | ORAL PHARMACEUTICAL COMPOSITIONS OF PROGESTERONE AND ESTRADIOL | ELENISTE, PIERRE PAUL | — |
| 18682824 | METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1622 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842742 | CHEWABLE ORAL CONTRACEPTIVE | PRAGANI, RAJAN | 1614 | §103DP | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18698961 | ORAL PHARMACEUTICAL COMPOSITIONS OF PROGESTERONE AND ESTRADIOL | ELENISTE, PIERRE PAUL | 1622 | §103 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18682824 | METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION | AZPURU, CARLOS A | 1617 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChemo Research S L has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Rajan Pragani has the most, with 1 of Chemo Research S L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
